Prescient Therapeutics (PTX) Short Interest
Prescient Therapeutics (ASX:PTX) had 0.00% of shares reported as short positions as of 13 Apr 2026, representing 10,996 shares. Prescient Therapeutics operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Prescient Therapeutics
Prescient Therapeutics is a clinical-stage oncology company focused on developing targeted therapies for cancer treatment. Their business model centers around advancing a diversified pipeline of assets, including PTX-100 in Phase 2a clinical development, and next-generation cell therapy platforms like OmniCAR and CellPryme, sourced from collaborations with leading research institutions.
Short position
Prescient Therapeutics (ASX:PTX) has 0.00% of its shares on issue reported as short positions as of 13 Apr 2026, or about 10,996 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.31% in January 2020. PTX is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Weekly context: The 10 most shorted ASX stocks — Week 37, 2026.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4PTX intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Prescient Therapeutics
Latest PTX news
All news- Update - Proposed issue of securities - PTX
asx · 7 Sept 2026
- Prescient Therapeutics - Extension of Share Purchase Plan
asx · 7 Sept 2026
- Prescient advances first-in-class cancer drug as big pharma shops for deals
stockhead · 7 Sept 2026
- Prescient lymphoma drug trial hits key review milestone
stockhead · 2 Sept 2026
- PTX-100 CTCL Phase 2a study reaches review milestone
asx · 1 Sept 2026
About
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss PTX
Start a research thread or post the first pulse update